Overview
Cyclana Bio is a Cambridge-based biotech company developing novel endometriosis therapeutics by targeting the extracellular matrix. The company builds tissue-level disease models using menstrual fluid biosamples and AI-driven multi-scale data integration to identify drug candidates and biomarkers. Their platform combines 3D tissue modeling, multi-omic data collection, and high-throughput screening to advance treatments for inflammatory and autoimmune conditions in women's health.
Frequently asked questions
- What is Cyclana Bio's primary therapeutic focus?
- Cyclana Bio focuses on developing treatments for endometriosis by targeting dysregulation of the extracellular matrix, which causes inflammation and loss of tissue function. The company aims to reverse scarring and develop novel therapeutic approaches through tissue-level disease modeling.
- What is Cyclana Bio's core technology platform?
- Cyclana Bio uses a tissue-level research platform combining menstrual fluid biosampling, multi-omic data collection, 3D hydrogel-based tissue models, and AI-driven data integration. This approach enables disease subtype stratification, progression prediction, and high-throughput target validation for drug candidate identification.
- What funding and development stage is Cyclana Bio at?
- Cyclana Bio raised £5 million in a pre-seed funding round co-led by NfX and Eka VC, with participation from Cocoa VC, Wilbe, and angel investors. The company is currently focused on validating its approach and building tissue models that accurately represent human disease pathology.
- Where is Cyclana Bio located and what is their research infrastructure?
- Cyclana Bio is based at the Babraham Research Campus in Cambridge, UK, within the LiveLabs premises. The location provides access to a unique ecosystem of biotech and academic innovation designed to support breakthrough discoveries in tissue biology and drug development.